20MG TABLETS ONCE WEEKLY
Treat patients until disease progression or unacceptable toxicity.1
Convenient , once-weekly oral dosing1
APPROPRIATE FLUID AND CALORIC INTAKE
Appropriate fluid and caloric intake should be maintained throughout treatment
AROUND THE SAME TIME EACH DAY 1 OF THE WEEK
If a dose is missed, continue regular dosing on the next scheduled day.1*
The recommended NEXPOVIO® + Bortezomib + dexamethasone doses on a 35-day cycle are as follows:1
NEXPOVIO® 100 mg*
Orally once weekly at approximately the same time on Day 1 of each week
Bortezomib 1.3 mg/m2
Subcutaneously once weekly on Day 1 of each week for 4 weeks followed by 1 week off
Dexamethasone 20 mg
Orally twice weekly on Days 1 and 2 of each week
Treatment with NEXPOVIO® combined with bortezomib and dexamethasone should be continued until disease progression or unacceptable toxicity.
* The dose of NEXPOVIO® should not exceed 70 mg/m2 per dose.1
NEXPOVIO® + Vd required less bortezomib, less dexamethasone, and fewer treatment administration visits compared with Vd in the first 24 weeks3
Dose modifications and reductions in patients receiving NEXPOVIO
NEXPOVIO® dosing can easily be adjusted to the individual patient1
Nexpovio dosage modification guidelines for ARs
NEXPOVIO® usage in special populations1
No specific dosing considerations required for:
Patients over 65 years of age
Mild, moderate, or severe renal impairment1
Mild hepatic impairments2
Selected Important Safety Information
Drug Interactions
No dedicated clinical drug interaction studies have been conducted.
Concomitant use of strong CYP3A4 inducer might lead to lower exposure of selinexor.
No clinically significant differences in selinexor pharmacokinetics were observed when co-administered with a strong CYP3A4 inhibitor, clarithromycin (500 mg PO twice daily for 7 days).
Special warnings and precautions for use
Recommended concomitant treatments Patients should be advised to maintain adequate fluid and caloric intake throughout treatment. Intravenous hydration should be considered for patients at risk of dehydration.
Prophylactic concomitant treatment with a 5-HT3 antagonist and/or other anti-nausea agents should be provided prior to and during treatment with NEXPOVIO (see section 4.8).
Please see additional Important Safety Information below. Please see full Prescribing Information.